Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Calgary

$150,000.00

Evaluation of Nanoparticles for the Treatment of Autoimmune Conditions

EF 2008-09

Résumé
Autoimmune disorders are debilitating, progressive and, at times, fatal conditions that affect millions of people globally, with 5.7 million in North America alone. There are over sixty identified diseases of this type that can cause either localised or systemic damage through an immune reaction mounted by a body against its own tissues. Type I Diabetes, Rheumatoid Arthritis, Lupus, Irritable Bowl Disease and Multiple Sclerosis are just a few examples of autoimmune disorders. Current therapies offer symptom management; however, none offer a cure for the autoimmune diseases. Additionally, the currently available therapies often have debilitating side effects and do not halt the progression of the disease. There is a need to develop curative therapies for autoimmune disorders. Dr. Santamaria has studied a novel mechanisms approach to the treatment of autoimmune disorders and has confirmed its viability in the NOD murine model of Diabetes. Currently, he is completing demonstration in a second animal model of Multiple Sclerosis. The research to date supports the methodology as a novel and potentially powerful approach to reverse the damaging effects of autoimmune responses. The focus is now shifting to developing the technology into a commercializable therapeutic treatment.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
175253
Name
Santamaria Pere
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Evaluation of Nanoparticles for the Treatment of Autoimmune Conditions
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Autoimmune Disease; Autoregulatory T Cells; Major Histocompatibility Complex (Mhc); Mice; Nanoparticles; Peptide; Prevention; Therapy; Type 1 Diabetes
Abstract
Autoimmune disorders are debilitating, progressive and, at times, fatal conditions that affect millions of people globally, with 5.7 million in North America alone. There are over sixty identified diseases of this type that can cause either localised or systemic damage through an immune reaction mounted by a body against its own tissues. Type I Diabetes, Rheumatoid Arthritis, Lupus, Irritable Bowl Disease and Multiple Sclerosis are just a few examples of autoimmune disorders. Current therapies offer symptom management; however, none offer a cure for the autoimmune diseases. Additionally, the currently available therapies often have debilitating side effects and do not halt the progression of the disease. There is a need to develop curative therapies for autoimmune disorders. Dr. Santamaria has studied a novel mechanisms approach to the treatment of autoimmune disorders and has confirmed its viability in the NOD murine model of Diabetes. Currently, he is completing demonstration in a second animal model of Multiple Sclerosis. The research to date supports the methodology as a novel and potentially powerful approach to reverse the damaging effects of autoimmune responses. The focus is now shifting to developing the technology into a commercializable therapeutic treatment.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Santamaria, Pere
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~